Clinical Trials Logo
  1. Home
  2. Advanced Lung Cancer
  3. NCT05431569

A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer

Advanced Lung Cancer Clinical Trial

Official title:
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer Who Had Failed Therapy With PD-1/L1 Inhibitor

Clinical Trial Summary

A non-randomized, open, Simon'soptimal2-stage study to evaluate the efficacy and safety of 6MW3211 in patients with advanced Lung Cancer who had failed therapy with PD-1/L1 Inhibitor.

Clinical Trial Description

36 to 64 patients with advanced lung cancer who failed pD-1 /L1 inhibitor treatment will be inrolled. Cohort 1:20 to 33 patients with non-small cell lung cancer (NSCLC) Cohort 2:16 to 31 patients with small cell lung cancer (SCLC) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05431569
Study type Interventional
Source Mabwell (Shanghai) Bioscience Co., Ltd.
Contact
Status Not yet recruiting
Phase Phase 2
Start date July 10, 2022
Completion date September 10, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04575831 - Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL) N/A
Completed NCT04069494 - Descriptors and Predictors of Burden and Information Needs
Terminated NCT03330834 - CAR-T Cell Immunotherapy for Advanced Lung Cancer Phase 1
Withdrawn NCT03004105 - MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) Phase 2
Withdrawn NCT03501056 - Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer Phase 2
Not yet recruiting NCT05279521 - The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer. N/A
Terminated NCT02768337 - Cambridge Brain Mets Trial 1 Phase 1/Phase 2
Completed NCT04672369 - A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC Phase 1
Recruiting NCT03751592 - Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer Phase 1/Phase 2
Not yet recruiting NCT06456138 - Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC Phase 1/Phase 2
Recruiting NCT06228209 - Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer N/A
Completed NCT04672356 - A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer Phase 1
Active, not recruiting NCT04670445 - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer N/A
Not yet recruiting NCT06107894 - TIL Therapy for Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06183762 - A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
Recruiting NCT05664971 - JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer Phase 1/Phase 2
Recruiting NCT05815862 - Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer Phase 2
Recruiting NCT05805956 - IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 Phase 1/Phase 2
Recruiting NCT06106152 - WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody Early Phase 1
Recruiting NCT05000684 - Study of JS004 Combined With Toripalimab for Advanced Lung Cancer Phase 1/Phase 2